Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Mourad Sanhaji, Frank Louwen, Brigitte Zimmer, Nina-Naomi Kreis, Susanne Roth & Juping Yuan. (2013) Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53. Cell Cycle 12:9, pages 1340-1351.
Read now
Read now
Articles from other publishers (19)
Xiao Wei, Mingzhu Song, Chan Huang, Qiao Yu, Guirong Jiang, Guanghao Jin, Xibiao Jia & Zheng Shi. (2023) Effectiveness, safety and pharmacokinetics of Polo-like kinase 1 inhibitors in tumor therapy: A systematic review and meta-analysis. Frontiers in Oncology 13.
Crossref
Crossref
Canjing Zhang, Huiwen Xu, Xianxian Sui, Lina Chen, Bobin Chen, Haozhen Lv, Songmei Wang & Xuanyi Wang. (2022) Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime. Molecular Therapy - Oncolytics 25, pages 288-304.
Crossref
Crossref
Chen-Yun Wang & Chi-Hong Chao. (2022) p53-Mediated Indirect Regulation on Cellular Metabolism: From the Mechanism of Pathogenesis to the Development of Cancer Therapeutics. Frontiers in Oncology 12.
Crossref
Crossref
Jiahao Hu, Jiasheng Cao, Win Topatana, Sarun Juengpanich, Shijie Li, Bin Zhang, Jiliang Shen, Liuxin Cai, Xiujun Cai & Mingyu Chen. (2021) Targeting mutant p53 for cancer therapy: direct and indirect strategies. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Pedro Novais, Patrícia M. A. Silva, Isabel Amorim & Hassan Bousbaa. (2021) Second-Generation Antimitotics in Cancer Clinical Trials. Pharmaceutics 13:7, pages 1011.
Crossref
Crossref
Nousheen Bibi, Ted Hupp, Mohammad Amjad Kamal & Sajid Rashid. (2021) Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1-Linked Functions Crosstalk. Protein & Peptide Letters 28:3, pages 340-358.
Crossref
Crossref
Iryna Kolosenko & Caroline Palm-Apergi. (2020) Small-molecule inhibitors for targeting polo-like kinase 1. Future Medicinal Chemistry 12:16, pages 1457-1460.
Crossref
Crossref
Souhayla El Maadidi, Alexander N. R. Weber, Precious Motshwene, Jan Moritz Schüssler, Daniel Backes, Sabine Dickhöfer, Hui Wang, Xiao Liu, Magno Delmiro Garcia, Christoph Taumer, Boumediene Soufi, Olaf-Oliver Wolz, Sascha N. Klimosch, Mirita Franz-Wachtel, Boris Macek & Nicholas J. Gay. (2019) Putative link between Polo-like kinases (PLKs) and Toll-like receptor (TLR) signaling in transformed and primary human immune cells. Scientific Reports 9:1.
Crossref
Crossref
Violeta Carmona‐Martínez, Antonio J. Ruiz‐Alcaraz, María Vera, Antonio Guirado, María Martínez‐Esparza & Pilar García‐Peñarrubia. (2018) Therapeutic potential of pteridine derivatives: A comprehensive review. Medicinal Research Reviews 39:2, pages 461-516.
Crossref
Crossref
Claudia Ctortecka, Vinayak Palve, Brent M. Kuenzi, Bin Fang, Natalia J. Sumi, Victoria Izumi, Silvia Novakova, Fumi Kinose, Lily L. Remsing Rix, Eric B. Haura, John Matthew Koomen & Uwe Rix. (2018) Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. Molecular & Cellular Proteomics 17:12, pages 2434-2447.
Crossref
Crossref
Erica G. Colicino & Heidi Hehnly. (2018) Regulating a key mitotic regulator, polo‐like kinase 1 (PLK1). Cytoskeleton 75:11, pages 481-494.
Crossref
Crossref
Carlos Murga-Zamalloa, Avery Polk, Walter Hanel, Pinki Chowdhury, Noah Brown, Alexandra C. Hristov, Nathanael G. Bailey, Tianjiao Wang, Tycel Phillips, Sumana Devata, Pradeep Poonnen, Juan Gomez-Gelvez, Kedar V. Inamdar & Ryan A. Wilcox. (2017) Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas. Oncotarget 8:70, pages 114474-114480.
Crossref
Crossref
Marie O. Pohl, Jessica von Recum-Knepper, Ariel Rodriguez-Frandsen, Caroline Lanz, Emilio Yángüez, Stephen Soonthornvacharin, Thorsten Wolff, Sumit K. Chanda & Silke Stertz. (2017) Identification of Polo-like kinases as potential novel drug targets for influenza A virus. Scientific Reports 7:1.
Crossref
Crossref
Tri Nguyen, Rebecca Parker, Elisa Hawkins, Beata Holkova, Victor Yazbeck, Akhil Kolluri, Maciej Kmieciak, Mohamed Rahmani & Steven Grant. (2017)
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur
in vitro
and
in vivo
and proceed through multiple mechanisms
. Oncotarget 8:19, pages 31478-31493.
Crossref
Crossref
Neil D. Palmisiano & Margaret T. Kasner. (2015) Polo‐like kinase and its inhibitors: Ready for the match to start?. American Journal of Hematology 90:11, pages 1071-1076.
Crossref
Crossref
Karineh Kazazian, Olga Brashavitskaya, Francis S. W. Zih, David Berger-Richardson, Roland S. Z. Xu, Karina Pacholczyk, Jennifer Macmillan & Carol J. Swallow. (2015) Polo-Like Kinases in Colorectal Cancer: Potential for Targeted Therapy. Current Colorectal Cancer Reports 11:4, pages 187-199.
Crossref
Crossref
Matthew D. Christensen, Jacob J. Elmer, Seron Eaton, Laura Gonzalez-Malerva, Joshua LaBaer & Kaushal Rege. (2015) Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression. Journal of Controlled Release 204, pages 20-29.
Crossref
Crossref
Surojit Sur, Anja C. Fries, Kenneth W. Kinzler, Shibin Zhou & Bert Vogelstein. (2014) Remote loading of preencapsulated drugs into stealth liposomes. Proceedings of the National Academy of Sciences 111:6, pages 2283-2288.
Crossref
Crossref
Marika A. RussoKristy S. KangAntonio Di Cristofano. (2013) The PLK1 Inhibitor GSK461364A Is Effective in Poorly Differentiated and Anaplastic Thyroid Carcinoma Cells, Independent of the Nature of Their Driver Mutations. Thyroid 23:10, pages 1284-1293.
Crossref
Crossref